Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095 - Wikidata - wikimedia - TriplyDB

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

http://www.wikidata.org/entity/Q28346436

about

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action Rodent models of diabetic nephropathy: their utility and limitations The Na(+)/glucose cotransporters: from genes to therapy Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes.Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.Comprehensive evidence-based assessment and prioritization of potential antidiabetic medicinal plants: a case study from canadian eastern james bay cree traditional medicine Renal hyperfiltration related to diabetes mellitus and obesity in human disease.Proinsulin maturation, misfolding, and proteotoxicity.LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats.SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models.Effects of phlorizin on diabetic retinopathy according to isobaric tags for relative and absolute quantification-based proteomics in db/db mice.Exercise-like effects by Estrogen-related receptor-gamma in muscle do not prevent insulin resistance in db/db mice.Advances in murine models of diabetic nephropathy.Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.A review of rodent models of type 2 diabetic skeletal fragility.Sodium-glucose transport: role in diabetes mellitus and potential clinical implications.SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.Pathophysiology of the diabetic kidney.The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.How the kidney hyperfiltrates in diabetes: From molecules to hemodynamics.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.Accumulation of worn-out GBM material substantially contributes to mesangial matrix expansion in diabetic nephropathy.miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes.Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function 5-(4-Ethoxy-benzyl)-1H-tetra-zole Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice Reduced renal sympathetic nerve activity contributes to elevated glycosuria and improved glucose tolerance in hypothalamus-specific Pomc knockout mice Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition.Mapping murine diabetic kidney disease using chemical exchange saturation transfer MRI.Green tea extract with polyethylene glycol-3350 reduces body weight and improves glucose tolerance in db/db and high-fat diet mice.

P2860

Q24684670-9B260F10-C2E6-40F6-A0BC-A369650C62D2 Q27027105-D19A242C-E91F-4768-B032-8A649B11D685 Q28073885-47EAC5FF-2511-4051-8813-C24C6ECF55FD Q28297657-BB3A4013-B6BD-4F7D-8EAA-CA2FA2BDF408 Q28732080-428A7F67-E1F8-4B35-8D35-6BF78ACDD4D8 Q35010970-E56BDAB2-9B8A-48CC-8E26-A408038417C8 Q35214420-27AAA7EA-9235-4018-AE2B-49F49126BBFA Q35548033-328FEADD-E2C2-40CB-B289-F8B4084969BA Q35636775-D818971F-BA3E-490F-ABD9-8018A841A515 Q35673442-4D4A9C78-A97B-4E93-801B-8BECD202AB1B Q36023668-BA3C2A84-ABB0-4C14-A210-F455D585647C Q36105649-62F1C72B-D472-4755-866D-F62B03463C4A Q36345951-1A8F57E5-E847-4A15-9829-7A324BEB1BC7 Q36440333-F3EA7477-FF7E-42C8-BB65-1A8F57E71F99 Q36745809-BE45D0F8-7F9D-4ADE-A834-978DC3E913B6 Q36765788-C0B2FD8F-73B3-4CCC-8D93-4F1BB0CCCD4C Q36933850-AA8F583D-80F2-4D73-BC91-990F9C21BED7 Q36971495-3C274A09-726A-42F2-BA6A-92F7B9B9F39C Q37219076-8B50D099-7660-4E38-BB58-0C796F280C74 Q37536310-9AA08036-097E-456B-9365-963C895AD678 Q37650212-CD190534-4C96-450A-92FC-7411B0810681 Q37764285-03FF3608-680C-4D14-AFEE-3A7E351708CA Q37872125-9AD200A3-CC94-45D1-9F52-6976A192C442 Q38111707-800A5B02-9D72-4375-A194-494980132D70 Q38126109-C0A0A948-90F2-4EF7-835E-FFE71514F947 Q38201162-04051DCF-9719-4613-95EB-DA1EE0409DD7 Q38490617-AC4DEC62-D199-4770-96E4-C963107362BE Q38775305-FB617DE2-6D44-449F-B8A4-9A4BBBBE9C51 Q38947594-774236D7-6216-4485-96A0-E4F13DF0AE53 Q39215725-6F925227-698A-4DB7-BA1F-A3D93EB4C402 Q40871412-C7445829-22AA-476F-90F0-A31C77A0DCC4 Q41579741-29789109-99B5-4FE4-BE75-B0861AA512EA Q42006157-75ABCBF4-BA46-430C-8724-358EB4AA2A19 Q42153763-B0528E1B-720E-4444-A64C-5E664E544688 Q42275930-6E899782-6A3A-40B7-BB25-817CB860B815 Q42329981-32CD2B22-8269-43E4-B11A-4F2FC9EF83B9 Q42377882-ACF4F99E-FF0B-4B16-9521-E4E3A8D2EF1B Q42554440-B7F0B52E-2DE3-4BF5-B528-15111DB7C07B Q42757817-D4BD3953-1EB7-4A24-87CA-CB54FD6E9731 Q43469951-6063E9AD-6FEA-4799-8FCC-0170AE7B3FF4

P2860

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

http://www.wikidata.org/entity/Q28346436

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@ast

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@en

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@nl

type

label

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@ast

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@en

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@nl

prefLabel

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@ast

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@en

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@nl

P1433

Q28346436-14657B6E-41EA-4CF4-A035-D9EAFAA63DA0

P1476

Q28346436-575650F3-59E3-4C1C-AECE-A1B09A301AD2

P2093

Q28346436-01FCE139-BC81-4342-B856-1BBF50F07845

Q28346436-41A49D3C-BC97-4DBF-B408-4895DE5FBDDC

Q28346436-5D1A3675-5FDB-44CE-8A1A-78C307D59513

Q28346436-83C37578-66FA-447A-8889-ED2C199AF523

Q28346436-84A790B0-0E49-45ED-B525-1F7AB7635D68

Q28346436-A0236627-C37B-4AE0-8C1A-E691FAC4E062

Q28346436-AAAC5810-EE16-43DC-B029-08EC8042DB56

Q28346436-DC019294-194D-4237-A4FF-75717FFA8D39

P2860

Q28346436-077EF9B7-86E1-4ED9-B072-C64CE767D55E

Q28346436-0828B598-6E4E-49F3-934D-7AEFCC1AAA54

Q28346436-09F11FB1-452E-4B96-95C1-409C39066A3D

Q28346436-3B0EF3F4-6F74-43D4-96C1-79B723BA0B25

Q28346436-3DC6C86E-B1B4-4E07-890D-4B61FE02073C

Q28346436-4D55D39E-E5AD-4C29-9533-D5417DC189F4

Q28346436-5C4F8DAD-F5EB-46A7-9445-408935E6F8F7

Q28346436-5E638A97-8166-49C1-B119-745A0C882E41

Q28346436-609B420A-76A2-46FF-BF25-0354982761BE

Q28346436-62C5DE8B-09F1-440C-BC7A-5215C537F086

P304

Q28346436-1A849B53-FBAF-40B6-A26A-6203CC726A2E

P31

Q28346436-74998116-8C32-432E-8C09-1467267B597D

P3181

Q28346436-542D129C-5A6A-48C2-ACE2-47B434526CED

P356

Q28346436-1B2BC096-7210-4CAB-BA09-9071C0198200

P407

Q28346436-7D474A3B-3B53-450B-BEAA-9AB0A801E7BD

P433

Q28346436-87F27726-74E5-4D02-88E8-044F458FE230

P478

Q28346436-D2A72CD5-D8DB-4ED5-8616-05365FFC2C32

P577

Q28346436-103F83E3-6E3C-44CA-8C26-A8D78058B626

P5875

Q28346436-3208F2B7-DBD2-45D9-B53B-DA20891CECEE

P698

Q28346436-71F7B824-9265-4F2A-A37F-D8A9B14C8E2B

P921

Q28346436-03f18295-bcb1-4e62-b72f-0017a142c379

P932

Q28346436-4557B36D-CE93-4B77-9674-905D9C560ED0

P3181

P356

P1433

British Journal of Pharmacology

P1476

Improved diabetic syndrome in ...... cotransporter inhibitor T-1095

@en

P2093

A Oku

http://www.w3.org/2001/XMLSchema#string

A Saito

http://www.w3.org/2001/XMLSchema#string

K Arakawa

http://www.w3.org/2001/XMLSchema#string

K Kitamura

http://www.w3.org/2001/XMLSchema#string

K Ueta

http://www.w3.org/2001/XMLSchema#string

M Matsumoto

http://www.w3.org/2001/XMLSchema#string

M Nawano

http://www.w3.org/2001/XMLSchema#string

T Ishihara

http://www.w3.org/2001/XMLSchema#string

P2860

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Hyperglycemia and microvascular and macrovascular disease in diabetes

Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4).

Phlorizin hydrolase: a beta-glucosidase of hamster intestinal brush border membrane.

Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations.

Structure and function of hexose transporters.

Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria?

Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?

Development of the insulin secretory defect in genetically diabetic (db/db) mouse.

Glucose transporters of the glomerulus and the implications for diabetic nephropathy.

P304

578-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1282899

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.BJP.0703829

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12169455

http://www.w3.org/2001/XMLSchema#string

P698

11159708

http://www.w3.org/2001/XMLSchema#string

P921

P932

1572576

http://www.w3.org/2001/XMLSchema#string